Global law firm Hogan Lovells has advised Recordati on the agreements for the acquisiton from Impact Biomedicines – a company wholly owned by Bristol-Myers Squibb K.K. – of the manufacturing and commercialization rights to Inrebic® in Japan. Inrebic® (generic name: fedratinib hydrochloride hydrate) is a drug for the treatment of myelofibrosis.
The cross-practice and multijurisdictional Hogan Lovells team that advised on the transaction was led by partners Francesco Stella and Penny Powell and included associates Bea Watts and James Furneaux from the London office, partners Frederick Ch’en and Hiroto Imai from the Tokyo office, and partners Audrey Reed and Cullen Taylor from the Washington office.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.